Aziyo Biologics/$ELUT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aziyo Biologics
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Ticker
$ELUT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
51
ISIN
US05479K1060
Website
Aziyo Biologics Metrics
BasicAdvanced
$87M
-
-$1.37
0.97
-
Price and volume
Market cap
$87M
Beta
0.97
52-week high
$3.46
52-week low
$1.61
Average daily volume
23K
Financial strength
Current ratio
0.815
Quick ratio
0.549
Long term debt to equity
-60.566
Total debt to equity
-68.616
Interest coverage (TTM)
-5.04%
Profitability
EBITDA (TTM)
-19.489
Gross margin (TTM)
43.53%
Net profit margin (TTM)
-168.23%
Operating margin (TTM)
-96.74%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
-38.41%
Return on equity (TTM)
92.37%
Valuation
Price to revenue (TTM)
2.921
Price to book
-2.37
Price to tangible book (TTM)
-1.86
Price to free cash flow (TTM)
-2.323
Free cash flow yield (TTM)
-43.05%
Free cash flow per share (TTM)
-91.04%
Growth
Revenue change (TTM)
-5.33%
Earnings per share change (TTM)
-42.03%
3-year revenue growth (CAGR)
-19.82%
3-year earnings per share growth (CAGR)
-17.79%
Aziyo Biologics News
AllArticlesVideos
New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices
GlobeNewsWire·3 weeks ago
Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method
GlobeNewsWire·2 months ago
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aziyo Biologics stock?
Aziyo Biologics (ELUT) has a market cap of $87M as of July 21, 2025.
What is the P/E ratio for Aziyo Biologics stock?
The price to earnings (P/E) ratio for Aziyo Biologics (ELUT) stock is 0 as of July 21, 2025.
Does Aziyo Biologics stock pay dividends?
No, Aziyo Biologics (ELUT) stock does not pay dividends to its shareholders as of July 21, 2025.
When is the next Aziyo Biologics dividend payment date?
Aziyo Biologics (ELUT) stock does not pay dividends to its shareholders.
What is the beta indicator for Aziyo Biologics?
Aziyo Biologics (ELUT) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.